Want to join the conversation?
$ARNA 2Q15 PR: "We have continued to advance our deep clinical-stage pipeline, as evidenced by the recent initiation of a Phase 2 proof-of-concept clinical trial of APD334, our internally discovered S1P1 receptor modulator, in ulcerative colitis," stated Jack Lief, CEO.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.